Question Bank › From candidate to default

From candidate to default

From candidate to default: the company has just been placed inside buyers' own purchasing systems

Calls Tested
498
Answered YES
12
Hit Rate
2.4%
rare by design

McCormick & Company, Incorporated (MKC) — this company's answers

NO on the Q2 2018 call 2018-06-28 C+
The model's full reasoning — Q2 2018 call → NO我们只需要根据提供的文本回答是或否。关键问题是管理层是否描述了公司最近从需要说服的候选者转变为已批准、指定、上市、合格、注册、报销或预先授权的选择,从而进入买方的采购、报销、处方集、规格、采购、网络、目录或计划系统,并且这种准入状态是新的,以至于大部分未来业务尚未反映在报告结果中。 扫描文本中是否有此类描述。管理层讨论了在零售商的货架空间、分销点、类别管理方面的进展,例如“Fix the Mix”计划、增加分销点、说服零售商移除重复的次要品牌等。这些听起来像是常规的销售和分销努力,而不是进入正式的采购系统。没有提到被列入批准的供应商名单、处方集、报销途径或类似内容。提到的“类别管理”和“货架空间”是零售分销,而不是采购系统。此外,任何提及的“新分销”或“货架空间”都是常规的零售销售活动。 关于“品牌食品服务”和“全国和区域客户”的提及,以及“菜单提及”和“前台存在”,这些可能暗示进入菜单或成为指定供应商,但文本没有明确说明公司被列入批准的供应商名单或类似系统。管理层提到“与全国和区域连锁账户的渗透增加”、“新增超过19,000个餐厅地点”等,但这些是销售胜利,而不是系统性的准入状态。 文本中没有任何内容表明公司最近获得了某种正式地位,使得未来业务无需单独销售即可自动流入。所有描述都是关于销售努力、分销增长和营销活动。因此,答案应为“否”。

← Back to the full MKC analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company has RECENTLY crossed from being a candidate that buyers must be persuaded to consider into being an APPROVED, SPECIFIED, LISTED, QUALIFIED, REGISTERED, REIMBURSED, OR PRE-AUTHORIZED choice inside buyers' own purchasing, reimbursement, formulary, specification, procurement, network, catalog, or program systems — so that a meaningful portion of the company's future business can now arrive WITHOUT a discrete selling event for each order — AND does management convey that this access status is new enough that most of the volume it will unlock is still ahead of the reported results? Answer YES when management's own words convey this ONE phenomenon, in whatever form fits the industry: the company has moved from candidate toward default inside the routine pathway through which purchases get made. Example forms, all treated equally: being named to an approved or preferred supplier list, procurement schedule, purchasing program, or payer network; being written into specifications, standards, reference designs, configurations, protocols, or bundled defaults; being added to a formulary, reimbursement catalog, coding/payment pathway, formulary-like listing, or provider directory; being qualified onto a customer's, agency's, platform's, or program's roster; or comparable status that inserts the company into the system through which transactions routinely flow. The essential point is the EXCHANGE OF FRICTION STATUS: buying no longer has to be re-argued each time, because the company is now inside the pathway. For YES, management must also convey, directly or plainly in substance, that the status is recent and the flow through it is only beginning — so the results just reported capture little of what this access will bring. One such gateway, or several together, both qualify. Answer NO if the only access described is ordinary selling relationships, routine reseller/distribution agreements, or standard customer wins where each order still must be individually persuaded. NO if the relevant status has existed for years and is simply the company's steady way of going to market, with nothing new about the access. NO if the status is only pending, applied for, hoped for, or contingent on approvals not yet obtained. NO if management merely asserts that the product is "mission-critical," "a standard," or "the default choice" without describing a concrete buyer-side system the company has been placed into. NO if the business flowing through that status is already mature and substantially reflected in current results. NO if the access status or its significance appears only in an analyst's question that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
WRBY Warby Parker Inc. Q1 2024 2024-05-09 A
AZEK The AZEK Company Inc. Q2 2024 2024-05-08 B+
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
INGN Inogen, Inc. Q1 2023 2023-05-05 F
HBB Hamilton Beach Brands Holding Company Q3 2022 2022-11-05 C
EVGO EVgo, Inc. Q2 2022 2022-08-09 C+
OPK OPKO Health, Inc. Q1 2022 2022-05-09 D
MGNI Magnite, Inc. Q1 2022 2022-05-04 D
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C

How the model reasoned

PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.

More from the question bank

Paying a named price today to serve businessEarnings outrunning the activityAnalysts converge on an emerging driverWorking harder than they are being paid forNumbers reset the ceilingDeliberately different by designAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.